Spago Nanomedical AB (OSTO:SPAGO) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:SPAGO Spago Nanomedical AB OSTO:SPAGO
34 GF Score
Price kr0.11
GF Value kr0.03
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Spago Nanomedical AB FFO?

FFO (Funds from operations) only applies to REITs.

OSTO:SPAGO
34GF Score
Spago Nanomedical AB OSTO:SPAGO
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Spago Nanomedical AB (OSTO:SPAGO) Overvalued in 2026?

Based on GuruFocus' analysis, Spago Nanomedical AB stock appears to be overvalued. The current stock price of kr0.11 is trading 278.3% above its estimated GF Value™ of kr0.03. GuruFocus considers Spago Nanomedical AB to be Significantly Overvalued.

Key valuation signals for OSTO:SPAGO:

  • FFO:
  • GF Value™: kr0.03 vs. price of kr0.11 (278.3% above fair value)
  • GF Score™: 34/100 with 4 warning signs

No single metric tells the full story. See the OSTO:SPAGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Spago Nanomedical AB Business Description

Address Scheelevagen 22, Lund, SWE, SE-223 63
Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through the previous detection of tumors and metastases. The Tumorad products focus on the development of a completely new form of radionuclide therapy for tumor-selective radiation therapy of cancer. The company's development projects are based on a platform of polymeric materials with various properties for the precise diagnosis and treatment of life-threatening and debilitating diseases.
34GF Score

Get the complete analysis for OSTO:SPAGO

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.11
Price
kr0.03
GF Value